Taymans Jill M reported option exercise involving 7,500 shares of CRYO CELL INTERNATIONAL INC at $3.10 for $23.3k on May 28, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
VP Finance, CFO
VP Finance, CFO
Filed May 29, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$23,250Shares × reported price
Shares traded
7,500Common Stock
Price per share
$3.10Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
52,896Direct
Trade date
May 28, 2026Option exercise
Filed
May 29, 2026, 4:30 PM ET1-day reporting delay
Accession
0001193125-26-248432Code M · Transaction 93595
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 28, 2026Option exercise7,500$3.10−$23,250Trade 93596
2 transaction rows in this filing. Joint filers share the same rows.

CCEL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CCEL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +3%1w ago +2.1%1d ago +0.6%
Returns since7d +3.9%30d −14%90d180d1y

Footnotes in full

F1: Stock options vest 1/5 per year commencing on September 23, 2020. F2: Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. F3: Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027. F4: Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028. F5: The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.